A comparative review of HLA associations with hepatitis B and C viral infections across global populations

Table 8 HLA Haplotype association with HCV viral clearance and persistence across global population

HLA	Effect	Country	NC	R	Chronic infection		Reference
					AC	CLC/CHC
Viral persistence
HLA Cw3- DR4-DQB1*0401 or *0402, and HLA-B61-DR4 -DQB1*0401 or 0402	VP/chronic infection	Japan	293			60	[69]
HLA B54-DRB1*0405-DQB1*0401 haplotype	VP-CLD	Japan	916		33	97	[68]
HLA DRB1*0405-DQB1*0401 haplotype	VP with LC	Japan	1216		50	67	[70]
HLA DRB1*0301, DQA1*0501, DQB1*0201	VP	Thailand	140	43	21	36	[133]
A*01-B*08-Cw*07-DRB1*03011-DQB1*0201	VP-CHC	Ireland		86		141	[60]
HLA DRB1*15-DQB1*0602	High viral load/increased risk for disease severity	Ireland (viremic females)				57	[71]
HLA A*11, C*04	VP	Ireland (Whites)		86		139	[56]
HLA DQA1*0201-DQB1*0201	Susceptibility to Chronic hepatitis C	Italy	179		41	99	[151]
HLA DR3/MICA-A4/B18	Susceptibility to chronic disease	Spain	116		48	93	[131]
HLA DRB1*0701-DQA1*0201-DQB1*02 and DRB1*1501-DQA1*01-DQB1*0602	VP-CLD	Poland	103			129	[108]
HLA DRB1*0301 -DQB1*0201	VP	USA					[77]
HLA-Cw*04-B*53	VP	USA		231		444	[58]
Viral clearance
HLA B44-DRB1*1302-DQB1*0604 and DRB1*1302-DQB1*0604	AC/no progression to CLD	Japan	916		33	97	[68]
HLA DRB1*0901-DQB1*0303	AC-no LC	Japan	1216		50	67	[70]
HLA A*03-B*07-DRB1*15-DQB1*0602 and A*02-B*27-Cw*01-DRB1*0101-DQB1*0501	VC/Protection from chronic infection	Ireland		86		141	[60]
DRB1*0701 and DQB1*02	Stable viral load/slow disease progression	Ireland (viremic females)				57	[71]
HLA DRB1*1104, DQA1*0501, DQB1*0301 haplotype	Protection from Chronic hepatitis	Italy	179		41	99	[151]
HLA DRB1*1104, DQB1*0301	VC	Italy	200	35	42	107	[138]
HLA DRB1*0101 -DQB1*0501 haplotype	Viral clearance (in white subjects)	USA		200		374	[77]

VP: Viral persistence; VC: Viral clearance; CHC: Chronic hepatitis C; CLD: Chronic liver disease; NC: Normal control; R: Recovered; AC: Asymptomatic carriers; LC: Liver cirrhosis.